Zai Lab Limited (NASDAQ:ZLAB) Insider Sells $115,230.00 in Stock

Zai Lab Limited (NASDAQ:ZLAB) insider Rafael Amado sold 3,000 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $38.41, for a total value of $115,230.00. Following the completion of the sale, the insider now directly owns 30,834 shares of the company’s stock, valued at $1,184,333.94. The trade was a 8.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Rafael Amado also recently made the following trade(s):

• On Tuesday, December 31st, Rafael Amado sold 7,583 shares of Zai Lab stock. The shares were sold at an average price of $26.28, for a total value of $199,281.24.

Zai Lab Trading Down 6.0 %

Shares of NASDAQ ZLAB opened at $35.09 on Friday. The company has a 50 day simple moving average of $30.70 and a two-hundred day simple moving average of $27.70. The stock has a market cap of $3.85 billion, a price-to-earnings ratio of -12.67 and a beta of 1.08. Zai Lab Limited has a 12 month low of $13.48 and a 12 month high of $39.61.

Zai Lab (NASDAQ:ZLAB) last posted its earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.19). The business had revenue of $109.07 million for the quarter, compared to analyst estimates of $110.15 million. Zai Lab had a negative net margin of 76.14% and a negative return on equity of 36.97%. Analysts forecast that Zai Lab Limited will post -2.58 EPS for the current year.

Institutional Trading of Zai Lab

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. purchased a new stake in Zai Lab in the 4th quarter worth approximately $29,000. Public Employees Retirement System of Ohio boosted its holdings in Zai Lab by 20.8% during the fourth quarter. Public Employees Retirement System of Ohio now owns 18,480 shares of the company’s stock worth $484,000 after buying an additional 3,179 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Zai Lab by 2.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 57,114 shares of the company’s stock valued at $1,496,000 after buying an additional 1,200 shares during the period. Woodline Partners LP increased its holdings in Zai Lab by 9.4% in the fourth quarter. Woodline Partners LP now owns 1,759,797 shares of the company’s stock valued at $46,089,000 after buying an additional 151,835 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new position in shares of Zai Lab in the fourth quarter worth about $7,857,000. 41.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ZLAB. Scotiabank started coverage on shares of Zai Lab in a report on Friday, March 7th. They set a “sector outperform” rating and a $55.00 price objective on the stock. JPMorgan Chase & Co. raised their price target on shares of Zai Lab from $44.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, March 13th. Cantor Fitzgerald raised shares of Zai Lab to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Bank of America restated a “neutral” rating and issued a $36.10 target price (up previously from $29.00) on shares of Zai Lab in a research note on Monday, March 3rd.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.